Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | YAP1 | P46937 | 2/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15083997 | 0.91 | CTSS (0.41) | CACNA1BMAPK1P2RX7YAP1CCKBR | |
| SCHEMBL15083928 | 0.87 | CACNA1B (0.39) | CACNA1BMAPK1YAP1CCKBRKMT2A | |
| SCHEMBL14822366 | 0.87 | CACNA1B (0.40) | CACNA1BMAPK1YAP1CCKBRKMT2A | |
| SCHEMBL15083936 | 0.86 | CACNA1B (0.36) | CACNA1BMAPK1YAP1CCKBRKMT2A | |
| SCHEMBL15083921 | 0.86 | CACNA1B (0.38) | CACNA1BMAPK1YAP1CCKBR | |
| SCHEMBL15083926 | 0.86 | JAK1 (0.37) | CACNA1BMAPK1YAP1CCKBRKMT2A | |
| SCHEMBL15084021 | 0.86 | GPR119 (0.44) | — | |
| SCHEMBL15084107 | 0.86 | CACNA1B (0.39) | CACNA1BMAPK1YAP1CCKBRKMT2A | |
| SCHEMBL15083924 | 0.85 | MCL1 (0.39) | — | |
| SCHEMBL15084117 | 0.84 | MAPK1 (0.40) | CACNA1BMAPK1YAP1CCKBRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172327-A1 | SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| WO-2013041497-A1 | SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172327-A1 | SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C | CTSS, CTSB, CTSG | CACNA1B 1227/4885MAPK1 3146/4885P2RX7 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.